+ Watch PIP
on My Watchlist
have to pick up at this price
PharmAthene will win its suit against Siga
With the settlement to the lawsuit with SIGA drawing near watch closely...My bet is on finding a win - win with siga
will be approved sooner than later
Short interest shows evidence of a bear paw on the scales since PIP won their lawsuit with SIGA - now facing analyst upgrades, actual payments from SIGA for ST 246, and entering trials on SparVax soon, those bears are likely to find that they are trapped.
.32 cents in projected 2013 earnings trading in the $1.50 area means a forward P/E of 5 which is too low. I will project .25 cents in earnings and and a forward P/E of 12 which puts my target at $3.00 per share or a full double from current prices.
First, let it be clear I am no expert and only have a lay view of the PIP v SIGA issues as an investor at one point in both firms. IMO your article is written in rather broad strokes - shooting from the hip as it were - clearly indicating your writer as a voice for MF has not looked into this case with an unbiased eye into the legal depth it deserves relative to Delaware law. For one, the LATS, written by PIP, was on paper marked by PIP as "non-binding" and had no final required approval by the relevant others of either company. What seems apparent is that PIP pursued the case in 2006, only after Siga experiments showed the drug's significant efficacy and after Siga paid back an earlier loan (at rather suitable interest) simply to stay afloat, whereas PIP has done no scientific work on the drug - only the loan and a LATS. PIP it seems tried to tie this loan to a LATS - arguing that the loan made the LATS binding; but, the bottom line appears to be that the firms only agreed to agree, without necessary formalization the LATS - I think this is the key issue for the judge to rule given Delaware law. Several other issues it seems the judge must render opinion on may result in a consequence that his ruling(s) could send this case into a virtually never ending appeal by either company, which may by law put the judge "between a rock and a hard place." The game by PIP it seems is 'dialing for dollars,' and the game recently has included chase by a private firm that has a purported smallpox antiviral drug. Coincidentally, the firm has by some opinions evoked an appearance of conflict via purported collusion with Rep Issa (GOP-CA) because the private firm and the Rep use the same lobbying firm. It seems also the firm's goal is to slow down Siga to try to get their own drug to a competitive point, given there is a 2Bil+ potential US and international market estimate raised in a now modified contract between the US/DHHS/BARDA for the Siga drug after FDA approval, an approval said to be within months. Again, I am no expert and claim only a layman's opinion, which may paint in whole or in part an imperfect picture, thus I claim shelter under my constitutional freedoms.
Increasing health care needs and pharmaceutical sales as US population ages.
Won the court fight w/ SIGA, and should get an OK settlement. The positive news from the announcement of the win (april) will be enough to push it up in the short term.
PIP's lawsuit is groundless because they themselves connoted the bottom of each page of the potential royalty agreement as "not binding". PIP's only hope is for some sort of negotiated settlement, which SIGA has repeatedly stated it would not do. The judge has hinted repeatedly that PIP's position is nothing more than a "crap shoot".Beyond this lawsuit, PIP has little income potential other than continued research grants from the government.
I smell privatization.
I agree with the seeking alpha article about the financial prospects of PIP, but unless this company can continually receive government contracts, here and abroad, we might see another huge loss in this company's worth, as in Jan of this year. I will consider this a cyclical investment with a time period of one year, with the hopes that PIP might be able to gain enough clout to keep selling to our gov. and to those abroad.Keep an eye on the competition. Or better yet, invest in both.
Jesus. PIP is a must buy at this point. The news keeps on getting better and better.
Likely to win the lawsuit and be entitled to 1B+ from government deal.
Major upside. January 2011 will be a big month as PIP will be involved in an important legal trial:http://seekingalpha.com/article/230259-why-pharmathene-could-go-from-2-to-20?source=TheMotleyFool
Here's the "gameplan"....Someone Pumps it, we run it, then we dilute it. Got it?Ready? BREAK!
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions